29 Background: 30 Endometrial cancer presents well-defined risk factors (myometrial invasion, 31 histological subtype, tumor grade, lymphovascular space invasion (LVSI)). Some 32 low and intermediate-risk endometrioid endometrial cancer patients exhibited 33 unexpected outcomes. The aim of this study was to investigate other clinical-34 pathological factors that might influence the recurrence rates of patients diagnosed 35 with low and intermediate-risk endometrioid endometrial cancer. 36 Methods: 37 A case-control study from a cohort retrospective of 196 patients diagnosed with 38 low and intermediate-risk endometrioid endometrial cancer at a single institution 39 between 2009 and 2014 was conducted. Medical records were reviewed to 40 compare clinical (race, smoking, menopause age, body mass index) and 41 pathological (histological characteristics (endometrioid vs endometrioid with 42 squamous differentiation), tumor differentiation grade, tumor location, endocervical 43 invasion, LVSI) features of patients with recurrence (case) and without recurrence 44 (control) of disease. Three controls for each case were matched for age and 45 staging.
Introduction

63
Endometrial cancer is the most prevalent gynecological neoplasia in women 64 in the US, accounting for more than 63,000 cases/year and with a lethality rate 65 close to 18%. 1 In Brazil, this tumor represents the second cause of gynecological 66 cancer due to a high incidence of tumors of the cervix. 2 As in other solid tumors, staging of endometrial cancer is important to define 72 surgical extension, ranging from hysterectomy with bilateral salpingo-73 oophorectomy even need pelvic and/or para-aortic lymphadenectomy. 4 Risk 74 stratification in stage I tumors aims to assess the risk of lymph node involvement, 75 the recurrence pattern, patient's prognosis and the best adjuvant treatment to be 76 performed. 5 Beyond myometrial tumor invasion depth, other clinical-pathological 77 factors were evaluated: age; histological subtype; tumor differentiation grade and 78 lymphovascular space invasion (LVSI). 6, 7 Beside these features, other 79 immunohistochemistry markers, such as L1-cell adhesion molecule (L1CAM) and 80 p53 are also associated with patient outcome for stage I endometrial cancer, but
81 not yet incorporated in the current classifications. 8 (Figure 1a and 1b) . A specific immunohistochemical marker used to 158 evaluate squamous lineage is p63, as shown in the inset (Figure 1c ). 17
159
There were no significant differences in race/ethnicity, ECOG performance 160 status, number of pregnancies, smoking history, tumor size, tumor localization and 161 LVSI between the group of patients with recurrence (cases) and patients without 162 recurrence (controls) ( Table 1) .
163
In the univariate analysis, four parameters with P < 0.2 were chosen for the 164 multivariate logistic regression analysis: hormonal status (menopause), tumor 165 differentiation grade, histological characteristics and endocervical invasion ( 253
The strengths of our study include the fact that all patients were treated at 254 the oncoginecology department from a tertiary cancer hospital where protocols are 255 followed closely. The pathology department is also divided into subspecialties, 256 surgical specimens description, sampling, and reporting are standardized, 257 resulting in high reproducibility of the pathology reports. Furthermore, the 258 methodology chosen was a well-matched case-control study by age and stage, 259 without differences between groups.
260
The limitations of the present study is its retrospective nature, associated 261 with the number of recurrent cases found (10.71%), despite agreeing with data 262 from literature since it is low and intermediate risk stage I tumors. 13 
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